Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma

Cancer Immunology, Immunotherapy

Volumn 61, Issue 9, 2012, Pages 1433-1439

  Ren, Shan ^a   Lu, Junfeng ^a   Du, Xiaofei ^a   Huang, Yanxiang ^a   Ma, Lina ^a   Huo, Honglei ^a   Chen, Xinyue ^a   Wei, Lai ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Genetic polymorphism; Hepatitis B virus (HBV); Hepatocellular carcinoma; Interferon ; Interleukin 28B

Indexed keywords

INTERLEUKIN 28B;

ADULT; ALLELE; ARTICLE; CANCER GROWTH; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEPATITIS B; HOMOZYGOSITY; HUMAN; IL28B GENE; INFECTION CONTROL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HEPATITIS B, CHRONIC; HUMANS; INTERLEUKINS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84866544912     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1203-y     Document Type: Article

References (27)

1. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576 (Pubitemid 46890874)
2. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
3. Schafer DF, Sorrell MF (1999) Hepatocellular carcinoma. Lancet 353:1253-1257 (Pubitemid 29168472)
4. Yang HI, Lu SN, Liaw YF et al (2002) Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347:168-174
5. Yu MW, Yeh SH, Chen PJ et al (2005) Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 97:265-272
6. Chen CJ, Yang HI, Su J et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73 (Pubitemid 43042691)
7. Iloeje U, Yang H, Su J, Jen C, You S, Chen C (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678-686 (Pubitemid 43374518)
8. Thio CL, Thomas DL, Carrington M (2000) Chronic viral hepatitis and the human genome. Hepatology 31:819-827 (Pubitemid 30169925)
9. Missiha SB, Ostrowski M, Heathcote EJ (2008) Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 134:1699-1714 (Pubitemid 351615412)
10. Sheppard P, Kindsvogel W, Xu W et al (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immuno l4:63-68 (Pubitemid 36104710)
11. Kotenko SV, Gallagher G, Baurin VV et al (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4:69-77 (Pubitemid 36109115)
12. Li M, Liu X, Zhou Y et al (2009) Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 86:23-32
13. Hong SH, Cho O, Kim K et al (2007) Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res 126:245-249 (Pubitemid 46726717)
14. Thomas DL, Thio CL, Martin MP et al (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798-801
15. Ge D, Fellay J, Thompson AJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401
16. Suppiah V, Moldovan M, Ahlenstiel G et al (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100-1104
17. Tanaka Y, Nishida N, Sugiyama M et al (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109
18. Robek MD, Boyd BS, Chisari FV (2005) Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79:3851-3854 (Pubitemid 40327973)
19. Ank N, West H, Bartholdy C et al (2006) Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80:4501-4509
20. Melchjorsen J, Siren J, Julkunen I et al (2006) Induction of cytokine expression by herpes simplex virus in human monocytederived macrophages and dendritic cells is dependent on virus replication and is counteracted by ICP27 targeting NF-kappaB and IRF-3. J Gen Virol 87:1099-1108
21. Hou W, Wang X, Ye L et al (2009) Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol 83:3834-3842
22. AbushahbaW, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E et al (2010) Antitumor activity of type I and type III interferons in BNL hepatomamodel.Cancer Immunol Immunother 59:1059-1071
23. Zitzmann K, Brand S, Baehs S, Goke B, Meinecke J, Spottl G et al (2006) Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun 344:1334-1341
24. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T (2006) Antitumor activity of IFN-lambda in murine tumor models. J Immunol 176:7686-7694 (Pubitemid 43849069)
25. Chi B, Dickensheets HL, Spann KM, Alston MA, Luongo C, Dumoutier L, Huang J, Renauld JC, Kotenko SV, Roederer M, Beeler JA, Donnelly RP, Collins PL, Rabin RL (2006) Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol 80:5032-5040
26. Zhang H (2010) Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 42:755-758
27. AnuradhaB, XinWW(2011) Power play: scoring our goals for liver cancer with better GWAS study design. J Hepatol 54:823-824